Daniel Markowitz

Stock Analyst at Evercore ISI Group

(3.17)
# 1,106
Out of 5,148 analysts
30
Total ratings
56.52%
Success rate
1.25%
Average return

Stocks Rated by Daniel Markowitz

Natera
Feb 27, 2026
Maintains: Outperform
Price Target: $250$260
Current: $200.17
Upside: +29.89%
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $155$170
Current: $147.00
Upside: +15.65%
Repligen
Feb 25, 2026
Maintains: Outperform
Price Target: $180$170
Current: $124.97
Upside: +36.03%
Guardant Health
Feb 20, 2026
Maintains: In-Line
Price Target: $105$110
Current: $92.23
Upside: +19.27%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $370$340
Current: $245.45
Upside: +38.52%
Bio-Techne
Feb 5, 2026
Maintains: In-Line
Price Target: $62$68
Current: $57.82
Upside: +17.61%
West Pharmaceutical Services
Feb 3, 2026
Maintains: Outperform
Price Target: $390$320
Current: $251.25
Upside: +27.36%
Rambus
Feb 3, 2026
Maintains: Outperform
Price Target: $126$119
Current: $98.88
Upside: +20.35%
DexCom
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $73.78
Upside: -7.83%
Inspire Medical Systems
Oct 7, 2025
Maintains: Outperform
Price Target: $150$125
Current: $64.81
Upside: +92.87%